Results 281 to 290 of about 3,371,263 (384)

Antipsychotic agents.

North Carolina medical journal, 1974
openaire   +1 more source

An open‐label study on ulotaront's effects on insulin‐glucose regulation in schizophrenia patients with metabolic syndrome and prediabetes: Part I

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 103-111, January 2026.
Abstract Aims Ulotaront is an investigational trace amine‐associated receptor 1 (TAAR1) agonist demonstrated to slow gastric emptying in schizophrenia patients with metabolic syndrome (MetSyn) and prediabetes type 2. Here we evaluate the effects of ulotaront on glucose‐insulin dynamics in schizophrenia patients with MetSyn and prediabetes.
Snezana Milanovic, Robert Lew, Kuangnan Xiong, Emily Casavant, Gerard Galluppi, Yu‐Luan Chen, Yongquan Lai, Manu Chakravarthy, Clay Dehn, Kenneth Koblan, Seth C. Hopkins   +10 more
wiley   +1 more source

Developing Topics. [PDF]

Alzheimers Dement
Chowdhury N, Pavoni C, Binns M, Ghosh S, Panda SS, Teleg E, Freedman M.   +6 more
europepmc   +1 more source

Risk of depression with GLP‐1 receptor agonists use in overweight or obese adults with type 2 diabetes: A new‐user, active‐comparator cohort study

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 197-209, January 2026.
Abstract Aims The association between glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and depression remains uncertain due to contradictory evidence. We compared the risk of incident depression between GLP‐1 RAs and sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) in overweight or obese adults with type 2 diabetes.
Yu Chang, Ming‐Hong Hsieh, Po‐Chung Ju, Cheng‐Chen Chang   +3 more
wiley   +1 more source

Body mass index and mental disorders: A Danish cohort study

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 306-315, January 2026.
Abstract Aims Low and high body weight present significant global health challenges and may be linked to specific mental disorders. Thus, we aimed to examine the associations between body mass index (BMI) and specific mental disorders. Materials and Methods In this Danish, population‐based cohort study using questionnaire and registry data, we included
Sigrid Bjerge Gribsholt, Kristina Laugesen, Oleguer Plana‐Ripoll, Sinna Pilgaard Ulrichsen, Mogens Vestergaard, Bjørn Richelsen, Ola Ekholm, Henrik Toft Sørensen   +7 more
wiley   +1 more source

Psychiatric effects of GLP‐1 receptor agonists: A systematic review of emerging evidence

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 50-59, January 2026.
Abstract This systematic review examines the current literature on glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs)‐associated psychiatric manifestations, including depression, suicidality, eating disorders, substance use disorders (SUD) and schizophrenia spectrum disorders.
Brianna Sa, Anthony Maristany, Ashwin Subramaniam, Ryan Guillen, Brooke Buonocore, Audrey Smith, Sean E. Oldak, Vanessa Padilla   +7 more
wiley   +1 more source

Helping people to discontinue antipsychotics: if, when and how. [PDF]

Schizophrenia (Heidelb)
Moncrieff J, Horowitz MA.
europepmc   +1 more source

Regular Medications Administered to Older Adults in Aged Care Facilities: A Retrospective Descriptive Study

Journal of Clinical Nursing, Volume 35, Issue 1, Page 363-374, January 2026.
ABSTRACT Aim(s) To explore which regularly prescribed medications are most commonly administered to older adults in aged care facilities in Australia, by whom and when, and to identify the prevalence of polypharmacy in this population group. Design Retrospective descriptive study.
Stephanie M. Garratt, Maneesh Prasad, Kelly Ottosen, Elizabeth Manias   +3 more
wiley   +1 more source

The Use of Long-Acting Injectables for People with Schizophrenia: Consensus Panel Recommendations for Overcoming Barriers and Implementing Treatment. [PDF]

Neurol Ther
Kane JM, Agid O, Castle DJ, Citrome L, Fagiolini A, Kishimoto T, Larrauri CA, Leucht S, Rubio JM, Sajatovic M, Schooler N, Correll CU.   +11 more
europepmc   +1 more source